Search company, investor...


Founded Year



Grant | Alive

Total Raised


Last Raised

$870K | 2 yrs ago

About Fujirebio

Fujirebio, fka Innogenetics, conceives, develops, produces and markets in vitro diagnostics (IVD) testing solutions.

Headquarters Location

Technologiepark 6

Ghent, 9052,


+32 9 329 13 29

Missing: Fujirebio's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Fujirebio's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Fujirebio Patents

Fujirebio has filed 85 patents.

The 3 most popular patent topics include:

  • Immunology
  • Clusters of differentiation
  • Molecular biology
patents chart

Application Date

Grant Date


Related Topics




Excipients, Analytical chemistry, Surfactants, Colloidal chemistry, Antiseptics


Application Date


Grant Date



Related Topics

Excipients, Analytical chemistry, Surfactants, Colloidal chemistry, Antiseptics



Latest Fujirebio News

Prostate Cancer Diagnostics Market will achieve USD 11.16 billion by 2030 : GreyViews

Jan 17, 2023

Major Players MDXHEALTH, F. Hoffmann-La Roche Ltd, Genomic Health, Inc., Siemens Healthcare GmbH, Abbott, Metamark Genetics, Inc., HUMASIS, FUJIREBIO, OPKO Health, Inc., bioMérieux, Inc., Siemens Healthcare GmbH, Diasorin S.P.A. among others. Segmentation Analysis Preliminary is expected to be the fastest-growing segment in 2022. The test type segment includes confirmatory and preliminary. The preliminary segment is expected to witness the highest growth rate during the forecast period. As prostate cancer is on the rise over the forecast period in the region, it is boosting the demand for the preliminary test segment. The American Institute for Cancer Research has noted that PSA screening has helped diagnose and treat early cancers, leading to an increase in survival rates. PSA tests detect small, unrecognized tumours which may or may not progress to advanced stages. Hospital-associated laboratories are expected to be the fastest-growing segment in 2022. The end-user segment includes cancer research institutes, hospital-associated laboratories and independent diagnostics laboratories. The hospital-associated laboratories segment is expected to witness the highest growth rate during the forecast period. In the global prostate cancer diagnostics market, hospital associated laboratories are expected to take the majority share during the forecast period because of an increase in prostate cancer cases. In the forecast period, the market growth will be driven by rising disease prevalence and technological advancements. Regional Analysis            The regional analysis provides a detailed perception of the key regions and the countries. Some of the key countries analyzed for the biomarkers market include the US, Canada, Mexico, Germany, France, the U.K., Italy, Spain, Russia, China, Japan, India, Brazil, Peru, UAE, South Africa, and Saudi Arabia. The North American region witnessed a major share. It is expected that North America will dominate the market due to factors such as increased prostate cancer prevalence, increased awareness, and the increasing number of research and development companies in this region. Prostate cancer cases are rising, creating huge opportunities for market players, and many are developing new and effective treatments. Country Analysis Germany Germany's prostate cancer diagnostics market size was valued at USD 0.83 billion in 2022 and is expected to reach USD 0.85 billion by 2030, at a CAGR of 13.5% from 2023 to 2030. Innovative products, growing awareness and government initiatives are all contributing to the growth of the prostate cancer diagnostics market. China China’s prostate cancer diagnostics market size was valued at USD 0.33 billion in 2022 and is expected to reach USD 0.92 billion by 2030, at a CAGR of 13.7% from 2023 to 2030. As China has a large population and therefore has more tests per capita than any other country in the region, China is expected to dominate the Asia-Pacific prostate cancer diagnostics market. India India's prostate cancer diagnostics market size was valued at USD 0.25 billion in 2022 and is expected to reach USD 0.69 billion by 2030, at a CAGR of 13.6% from 2023 to 2030. The availability of a wide range of products, adjustments in consumption patterns, improved lifestyles, and an increase in personal care spending are anticipated to contribute to the growth of the nail industry in the future. The popularity of nail polish and nail art has increased in the country due to a growing party culture as well as a variety of festivals and functions. Covid-19 Impact Covid-19 had a major impact on almost all industries, such as electronics, semiconductors, manufacturing, automobile, etc. However, several companies operating in the technology sector have seen increased revenue due to significant changes in consumer preferences toward technological services. In addition, the pandemic has led to significant growth in technology across developing and developed countries. Furthermore, the growth of this market is mainly driven owing to the increase due of the rising cases of cancer and cardiovascular diseases, propelling the growth of the market across the countries. Buy Now Full Report @ Contact Us

Fujirebio Frequently Asked Questions (FAQ)

  • When was Fujirebio founded?

    Fujirebio was founded in 1985.

  • Where is Fujirebio's headquarters?

    Fujirebio's headquarters is located at Technologiepark 6, Ghent.

  • What is Fujirebio's latest funding round?

    Fujirebio's latest funding round is Grant.

  • How much did Fujirebio raise?

    Fujirebio raised a total of $870K.

  • Who are the investors of Fujirebio?

    Investors of Fujirebio include Vlaams Innovatiefonds, Alta Berkeley and Capricorn Partners.

  • Who are Fujirebio's competitors?

    Competitors of Fujirebio include Acumen Pharmaceuticals, Euroclone SpA, DermTech International, RevDia, CellXplore and 11 more.

Compare Fujirebio to Competitors


CellXplore is a new, biotechnology company engaged in the development of biomarker-based in vitro diagnostic assays for cancer, initially focusing on breast cancer. Although mammography is an effective screening test for early detection, there is a need for a simple, reliable and sensitive biomarker-based in vitro assay that can be used to stage and characterize breast cancer.nThe company was formed to commercialize groundbreaking discoveries demonstrating up-regulation of the ubiquitin-proteasome pathway in cancerous breast tissue, providing the capability for the noninvasive detection of breast cancer and the ability to monitor the efficacy of chemotherapeutic interventions.nCellXplore's platform technology is not restricted to breast cancer in vitro diagnostics alone, nor is it restricted to cancer diagnostics alone. Beyond cancer, CellXplore is already investigating whether similar blood sample biomarkers can be identified for the early diagnosis of several major debilitating diseases such as muscle wasting, Alzheimer's disease, Parkinson's disease and inflammatory diseases.


Onconix, Inc. is an intellectual property, biotechnology company focused on identifying and marketing diagnostic technologies from various research settings, which have undergone peer review. Currently, Onconix has exclusive rights to market and develop promising new tests for cervical cancer.


RevDia is a provider of a therapeutic diagnostic testing platform. The company's diagnostic testing platform is designed to detect an active periodontal infection. Its technology is intended to measure elevated levels of slgA in saliva that is specific to Aa and Pg virulence proteins, an attribute displayed by bacteria when it becomes pathogenic during an active infection.


The principal aims of Shardna are the identification of genetic variants to common diseases, the structural and functional characterization of apposite protein through the study of the genetic, genealogical, epidemiological, environmental and behavioural properties of specific isolated and genetically homogenous populations in the Ogliastra region of Sardinia. The results of the project will be capped by the development of diagnostics, and therapeutic and pharmacological treatment for the cure or prevention of multifactorial illnesses. The knowledge-based system which will be used in this endevour will be of particular interest to pharmaceutical and biotech businesses working to develop drugs and diagnostic tools.

Panacea Pharmaceuticals

Panacea Pharmaceuticals, founded in 1999, discovers, develops, and commercializes novel therapeutic and diagnostic products for oncology and diseases of the central nervous system. Since its inception, the Company's primary approach to cancer treatment has been immunotherapy and development of companion diagnostics for comprehensive patient management. The Company's lead drug product candidate is a nanoparticle-based therapeutic cancer vaccine that targets a novel patented tumor marker, human aspartyl (asparaginyl) -hydroxylase (HAAH).

CELLective Dx Corporation

CELLective Dx is an early-stage company developing a new generation of diagnostic tools for cancer based on analysis of CTCs directly from a patient's blood. Our novel proprietary technologies combine microfluidics, flow dynamics, cell biology, molecular biology, biochemistry, and surface chemistry to capture and analyze rare CTCs in blood more rapidly and effectively than other current technologies. CELLective Dx is developing simple, rapid, blood-based cancer tests that will provide physicians and patients with accurate and individualized clinical information on disease status, treatment selection, and treatment response that will dramatically improve the clinical management of cancer.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.